Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 8/20 | 0.65 |
| ▸ | KDM5C | P41229 | 6/20 | 0.65 |
| ▸ | KDM4A | O75164 | 5/20 | 0.65 |
| ▸ | ALKBH5 | Q6P6C2 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | KDM6B | O15054 | 4/20 | 0.65 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.65 |
| ▸ | KDM3A | Q9Y4C1 | 4/20 | 0.65 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.65 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TET3 | O43151 | 1/20 | 0.65 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | KDM5A | P29375 | 1/20 | 0.65 |
| ▸ | ASPH | Q12797 | 1/20 | 0.65 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.65 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.65 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.65 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6975486 | 1.00 | FTO (0.65) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL2225645 | 1.00 | FTO (0.65) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL20944112 | 0.86 | KDM5C (0.65) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL20944111 | 0.86 | KDM5C (0.65) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL7720509 | 0.82 | KDM5C (0.74) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL30745058 | 0.81 | KDM4E (0.55) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL29278627 | 0.81 | KDM4E (0.55) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL20963391 | 0.81 | KDM4E (0.55) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL19616074 | 0.79 | FTO (0.65) | FTOKDM5CKDM4AALKBH5KDM4E | |
| SCHEMBL28835413 | 0.79 | FTO (0.65) | FTOKDM5CKDM4AALKBH5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | FTO 3894/4885KDM5C 3267/4885KDM4A 1960/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | FTO 3894/4885KDM5C 3267/4885KDM4A 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.